Characteristics of HIV-infected subjects.

VL, plasma HIV-1 RNA viral load; (c)ART, (combination) anti-retroviral therapy; AZT, zidovudine; d4T, stavudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine; ABC, abacavir; TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; FOS-APV, fosamprenavir; RTV, ritonavir at therapeutic dose;/r, ritonavir at pharmacokinetic boosting dose; MVC, maraviroc; RAL, raltegravir; UK, unknown; NA, not available; COX, cytochrome c oxidase. COX data (but not MRS data) from 5 subjects has been previously described [8].